Pefloxacin for Falciparum Malaria: Only Modest Success

Abstract

Brief Reports15 May 1991Pefloxacin for Falciparum Malaria: Only Modest SuccessPhilippe Deloron, MDPhD, Jean Paul Lepers, MD, Lucie Raharimalala, MD, Béatrice Dubois, MA, Pierre Coulanges, MD, Jean Jacques Pocidalo, PhDPhilippe Deloron, MDPhDSearch for more papers by this author, Jean Paul Lepers, MDSearch for more papers by this author, Lucie Raharimalala, MDSearch for more papers by this author, Béatrice Dubois, MASearch for more papers by this author, Pierre Coulanges, MDSearch for more papers by this author, Jean Jacques Pocidalo, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-10-874 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe spread of chloroquine-resistant Plasmodium falciparum strongly indicated the need for new safe and effective antimalarial drugs. In addition to their antibacterial action, fluoroquinolone antibiotics inhibit P. falciparum in vitro (1). Pefloxacin is effective against P. yoelii infection in mice (2), and norfloxacin, the main metabolite of Pefloxacin in humans, was reported to cure P. falciparum malaria in 9 adults in India (3). Therefore, we assessed the efficacy of Pefloxacin in treating chloroquine-resistant P. falciparum malaria in Madagascar (4).Patients and MethodsIn Ankazobe, 95 km west of Antananarivo, the capital of Madagascar, blood was collected from 396 adults to...